文献速递免疫规划卫生政策与健康促进

印尼国家免疫规划引入伤寒结合疫苗的成本效果与预算影响分析

Cost-effectiveness and budget impact analyses of introducing typhoid conjugate vaccine into Indonesia's national immunisation program.
PubMed 文献 · Vaccine · 2026-08-08

研究评估印尼9月龄常规接种伤寒结合疫苗(TCV)及追加15岁以下补种活动的成本效果与预算影响。动态模型模拟30年,常规接种ICER为每避免1个DALY 240.6美元(卫生系统视角),加补种为521.3美元,均具成本效果;补种联合策略为最优策略。

要点

  • 常规TCV接种ICER为240.6美元/DALY(卫生系统视角),约人均GDP的5%。
  • 常规加补种ICER为521.3美元/DALY,约人均GDP的11%。
  • 补种联合策略在1倍人均GDP阈值下成本效果概率99.7%,为最优策略。

核心结论

  • 印尼国家免疫规划引入TCV预计极具成本效果。
  • 仅常规接种预算需求较低,但加补种活动为公共卫生影响更大的最优策略且仍极具成本效果。

研究设计与样本

  • 采用经验证的伤寒传播动态模型,对每个场景预测30年健康结局。
  • 成本数据来自印尼伤寒监测研究和已发表文献,从卫生系统和社会视角估算ICER。
  • 不确定性分析采用单因素敏感性分析(OWSA)和概率敏感性分析(PSA),并做预算影响分析支持年度财政规划。

主要发现

  • 常规接种预算占年度国家免疫预算的0.48%-2.95%,常规加补种占2.97%-9.84%。
  • 与不接种相比,常规TCV卫生系统视角ICER为240.6美元/DALY,社会视角238.8美元/DALY,对应人均GDP的5%。
  • 与仅常规接种相比,加补种卫生系统视角ICER为521.3美元/DALY,社会视角519.5美元/DALY,约人均GDP的11%。
  • PSA显示成本效果概率:常规加补种对比常规为99.7%,常规对比不接种为99.2%;多策略成本效果可接受曲线确定常规加补种为最优策略。

关键数值与推荐

  • OWSA显示两种策略在1倍人均GDP支付意愿阈值下均保持极具成本效果。

临床怎么用

  • 印尼可将9月龄常规TCV接种纳入国家免疫规划,若预算允许可追加15岁以下补种活动以增强公共卫生影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Typhoid fever remains a health threat in endemic countries. In Indonesia, it causes an estimated 470,000 cases and 6000 deaths annually. We assessed the cost-effectiveness and budget impact of introducing the typhoid conjugate vaccine (TCV) into Indonesia's routine National Immunisation Program (NIP) at 9 months of age, with or without a catch-up campaign up to 15 years of age. METHODS: A validated dynamic model of typhoid transmission was used to project health outcomes over a 30-year analytical horison for each scenario. Cost-of-illness data were drawn from the Surveillance of Typhoid Fever in Indonesia study and published literature. Incremental cost-effectiveness ratios (ICERs) were estimated from healthcare sector and societal perspectives. Uncertainty was explored using one-way sensitivity analysis (OWSA) and probabilistic sensitivity analysis (PSA). Budget impact analysis supported annual fiscal planning. RESULTS: Six-year budget impact costs were US$61 million (routine) and US$251 million (routine and catch-up), equivalent to 0.48%-2.95% and 2.97%-9.84% of the annual national immunisation budget, respectively. Compared to no vaccination, routine TCV yielded ICERs at US$240.6 and US$238.8 per DALY averted from the healthcare sector and societal perspectives, respectively, corresponding to 5% of GDP per capita. Compared with routine immunisation alone, adding a catch-up campaign yielded ICERs of US$521.3 and US$519.5 per DALY averted from the healthcare sector and societal perspective, respectively, corresponding to approximately 11% of GDP per capita. OWSA showed that both strategies remained very cost-effective at a willingness-to-pay threshold of 1xGDP. PSA estimated probabilities of cost-effectiveness of 99.7% (routine and catch-up vs. routine) and 99.2% (routine vs. no vaccination). The multi-strategy cost-effectiveness acceptability curve identified the combined routine and catch-up campaign as the optimal strategy. CONCLUSION: Introducing TCV into Indonesia's NIP is projected to be very cost-effective. A routine-only program requires a lower budget, but adding a catch-up campaign is an optimal strategy with greater public health impact while remaining very cost-effective. FUNDING: Gates Foundation grants to Murdoch Children's Research Institute in collaboration with Universitas Gadjah Mada [ref. no. INV-003867] and to TyVAC 2.0 [ref. no. INV-030857].

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Haposan JH, Thobari JA, Watts E, et al. Cost-effectiveness and budget impact analyses of introducing typhoid conjugate vaccine into Indonesia's national immunisation program. Vaccine. 2026. PMID: 42570462. doi:10.1016/j.vaccine.2026.129008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。